lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | ≥ 95 % of peak area by HPLC | Some suppliers quote 98 % or higher |
| Identity confirmation | Mass spectrometry (electrospray or MALDI) | Observed mass is compared with the calculated mass |
| Common analytical method | Reversed-phase HPLC on a C18 column | Acetonitrile and water gradients with trifluoroacetic acid |
| Primary degradation route | Oxidation of the methionine residue | Yields a sulfoxide that separates cleanly on chromatography |
| Storage of dissolved material | Aliquoted and frozen at −20 °C or below | Single-use aliquots avoid repeated temperature cycling |
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
=== Indigenous rights === Findlay has also made opposition to Indigenous rights, including the repeal of DRIPA, core to her platform while campaigning for leadership of the BC Conservative Party. She accused leadership rival Peter Milobar of having a conflict of interest in how he handled opposition to the legislation because his wife and other family members were Indigenous, which led to accusations of racism. In her acceptance speech as leader, she doubled down, stressing “The NDP’s radical ideology has devastated property rights, backroom-signed treaties, and the NDP’s economic vandalism has to end.” Findlay and her staff were also alleged to have issued guidance to several caucus members and their staffers that they were to use the terms Indigenous, Aboriginal or Indian instead of First Nations. Her office was said to have cited the federal Indian Act as justification for using this term. When questioned by Black Press, she denied the allegations, claiming “It’s simply not true. There was no directive, nothing like that.”
Initiatives since 2007 made English medium education mandatory nationwide. Following a 2012 attack on activist Malala Yousafzai by the Taliban, she became the youngest Nobel laureate for her education advocacy. Reforms in 2013 mandated Chinese language courses in Sindh, reflecting China's growing influence. As of 2018, Pakistan's literacy rate stands at 62.3%, with significant regional and gender disparities. Government initiatives, including computer literacy since 1995, aim to eradicate illiteracy, targeting 100% enrollment among primary school-age children and an ~86% literacy rate by 2015. Pakistan allocates 2.3% of its GDP to education, among the lowest in South Asia.
=== Biosignaling === For isopeptide bonds linking one protein to another for the purpose of signal transduction, the literature is dominated by ubiquitin and other similar proteins. Ubiquitin and its related proteins (SUMO, Atg8, Atg12, etc.) all tend to follow relatively the same protein ligation pathway. The process of protein ligation by ubiquitin and ubiquitin-like proteins has three main steps. In the initial step, the specific activating protein (E1 or E1-like protein) activates Ubiquitin by adenylating it with ATP. Then the adenylated Ubiquitin can be transferred to a conserved cysteine using a thioester bond which is between the carboxyl group of the C-terminal glycine of the ubiquitin and the sulfur of the E1 cysteine. The activating E1 enzyme then binds with and transfers the Ubiquitin to the next tier, the E2 enzyme which accepts the protein and once again forms a thioester with a conserved bond. The E2 acts to certain degree as an intermediary which then binds to E3 enzyme ligase for the final tier, which leads to the eventual transfer of the ubiquitin or ubiquitin related protein to a lysine site on the targeted protein, or more commonly for ubiquitin, onto ubiquitin itself to form chains of said protein. However, in final tier, there is also a divergence, in that depending on the type of E3 ligase, it may not actually be causing the conjugation.
Sources: en.wikipedia.org
However, others have pointed out that C-peptides are produced in hypoglycaemic attacks caused by insulin produced naturally in the body, and these were not detected in any of the blood tests of the victims, indicating that the insulin had been introduced to their bodies externally and artificially. Norris lost an appeal against his conviction in 2009. In February 2021, the Criminal Cases Review Commission referred the case back to the Court of Appeal; this second appeal, heard in 2025, was also unsuccessful. Norris is believed to have been inspired by Jessie McTavish, a fellow Scottish nurse who was convicted of murdering a patient with insulin in 1974 before having her conviction quashed in 1975. The incident had happened at Ruchill Hospital in Glasgow, less than a mile from where Norris grew up. Shortly before he registered as a nurse, he had learned about McTavish.
Inside the brain norepinephrine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. After synthesis, norepinephrine is transported from the cytosol into synaptic vesicles by the vesicular monoamine transporter (VMAT). VMAT can be inhibited by Reserpine causing a decrease in neurotransmitter stores. Norepinephrine is stored in these vesicles until it is ejected into the synaptic cleft, typically after an action potential causes the vesicles to release their contents directly into the synaptic cleft through a process called exocytosis. Once in the synapse, norepinephrine binds to and activates receptors. After an action potential, the norepinephrine molecules quickly become unbound from their receptors. They are then absorbed back into the presynaptic cell, via reuptake mediated primarily by the norepinephrine transporter (NET). Once back in the cytosol, norepinephrine can either be broken down by monoamine oxidase or repackaged into vesicles by VMAT, making it available for future release.
=== Initial development === A predecessor compound of minoxidil was developed in the late 1950s by the Upjohn Company (later became part of Pfizer) to treat ulcers. In trials using dogs, the compound did not cure ulcers but proved to be a powerful vasodilator. Upjohn synthesized over 200 variations of the compound, including the one it developed in 1963 and named minoxidil. These studies resulted in the U.S. Food and Drug Administration (FDA) approving minoxidil (with the brand name Loniten) in the form of oral tablets to treat high blood pressure in 1979.
The two substrates of this enzyme are (S)-malic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are oxaloacetic acid, NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-malate:NADP+ oxidoreductase. Other names in common use include NADP+-malic enzyme, NADP+-malate dehydrogenase, malic dehydrogenase (nicotinamide adenine dinucleotide phosphate), malate NADP+ dehydrogenase, NADP+ malate dehydrogenase, NADP+-linked malate dehydrogenase, and malate dehydrogenase (NADP+). This enzyme participates in pyruvate metabolism and carbon fixation. This enzyme has at least one effector, hn.
Sources: en.wikipedia.org
This decrease is almost unnoticeable if a smooth aneurysm is produced in the wall of a capillary by heating and pressurization, as plug flow can be preserved. This invention by Gary Gordon, US Patent 5061361, typically triples the absorbance path length. When used with a UV absorbance detector, the wider cross-section of the analyte in the cell allows for an illuminating beam twice as large, which reduces shot noise by a factor of two. Together these two factors increase the sensitivity of Agilent Technologies's Bubble Cell CE Detector six times over that of one using a straight capillary. This cell and its manufacture are described on page 62 of the June 1995 issue of the Hewlett-Packard Journal.
== Gene == There are an estimated 30 people in the world that have been diagnosed with the congenital form of Factor II deficiency, which should not be confused with the prothrombin G20210A mutation, which is also called the factor II mutation. Prothrombin G20210A is congenital. Prothrombin G20210A is not usually accompanied by other factor mutations (i.e., the most common is factor V Leiden). The gene may be inherited heterozygous (1 pair), or much more rarely, homozygous (2 pairs), and is not related to gender or blood type. Homozygous mutations increase the risk of thrombosis more than heterozygous mutations, but the relative increased risk is not well documented. Other potential risks for thrombosis, such as oral contraceptives may be additive. The previously reported relationship of inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis) and prothrombin G20210A or factor V Leiden mutation have been contradicted by research.
== See also == Madrigal v. Quilligan No más bebés Sterilization law in the United States Eugenics in the United States Sterilization of Native American women Compulsory sterilization Anti-Mexican sentiment Chicano Movement Abortion rights movements East L.A. Walkouts Women's Rights
Sources: en.wikipedia.org
Suppliers normally quote a percentage of total chromatographic peak area, most often from reversed-phase HPLC. That figure says nothing about what the remaining percentage contains, and it depends on the detection wavelength used. A mass spectrometry result is a separate and stronger check on identity.
The methionine residue at the start of the chain is vulnerable to oxidation, producing a sulfoxide variant. Amide bonds can also hydrolyze, though more slowly under neutral conditions. Cold storage, oxygen exclusion and minimization of freeze-thaw cycles slow both processes but do not stop them.
A purity number on a certificate does not establish that a powder is the same product as a registered nasal medicine. Counter-ion content, residual solvents and peptide-related impurities may differ between the two. Independent verification is the only way to narrow that gap.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.